# Hydrochlorothiazide

Drug · id `cardio:hydrochlorothiazide` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: HCTZ

Browse, organ or system: Heart; Kidneys  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

Hydrochlorothiazide is a thiazide diuretic taken by mouth. The US label read is for hydrochlorothiazide tablets and lists two uses: adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy (the label also names edema from kidney disease as a use it has been found useful for); and the management of hypertension, as the sole agent or, in the more severe forms of hypertension, to enhance other antihypertensive drugs. The label's separate passage on diuretics in pregnancy was not recorded. Combination products that contain hydrochlorothiazide have their own labels and are not described here.

## Technical summary

RxNorm ingredient 5487; UNII 0J48LPH2TH. MeSH descriptor D006852 is Hydrochlorothiazide. Class: Thiazide Diuretic (FDA established pharmacologic class, RxClass). The label read is the hydrochlorothiazide tablets, Aurobindo Pharma Limited label, effective 2024-06-26 in openFDA (application ANDA040780). Other hydrochlorothiazide labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of hydrochlorothiazide tablets lists an indication: edema (including edema of congestive heart failure), hypertension

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of hydrochlorothiazide tablets, in the Aurobindo Pharma Limited version dated 2024-06-26 in openFDA, lists the medicine as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy, and in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for hydrochlorothiazide tablets, Aurobindo Pharma Limited label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 01f1f478-5493-439f-9b99-f4f82023781c (manufacturer Aurobindo Pharma Limited, application ANDA040780), returned on 2026-11-09. The label text is dated 2024-06-26 (effective\_time). Other openFDA records of hydrochlorothiazide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2201f1f478-5493-439f-9b99-f4f82023781c%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-11-09T13:17:57Z. Source state: Current. Version fingerprint: cc53f95717d74809d63ae95a14078f0ca4d3da6de792140deebbaf4f025c5549.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for hydrochlorothiazide tablets, Aurobindo Pharma Limited label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 01f1f478-5493-439f-9b99-f4f82023781c (manufacturer Aurobindo Pharma Limited, application ANDA040780), returned on 2026-11-09. The label text is dated 2024-06-26 (effective\_time). Other openFDA records of hydrochlorothiazide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2201f1f478-5493-439f-9b99-f4f82023781c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:57Z. Source state: Current. Version fingerprint: cc53f95717d74809d63ae95a14078f0ca4d3da6de792140deebbaf4f025c5549.
     How it applies: Effective date of the label text read, 20240626.

## Connected pages

- Hydrochlorothiazide is a thiazide diuretic (FDA established pharmacologic class in RxClass): Thiazide and thiazide-like diuretics (`cardio:thiazide-and-thiazide-like-diuretics`)
- FDA label lists the management of hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-hydrochlorothiazide-label-indications` and its context]
- FDA label lists adjunctive therapy in edema associated with congestive heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-hydrochlorothiazide-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 40 registry products
- 16 registry trials

## Provenance

Content hash: 0b2f5bf56f0ca2a1367a7afa16c5d7ca76a978812607810c987c4427ad322e45
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
